Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PMZ-2123
- Development stage
- Unknown
- Lead developer
- Pharmazz
- Modality
- Peptides
- Administration
- Intravenous
01
Overview
**PMZ-2123** is a cyclic peptide endothelin-A receptor antagonist isolated from *Streptomyces misakiensis*, previously known as BQ-123, under development by Pharmazz, Inc. for critical care indications. It blocks endothelin-A receptors to mitigate vasoconstriction and neurological damage, showing preclinical efficacy in reversing opioid tolerance by restoring analgesic effects of morphine and oxycodone via intravenous administration, preventing neurological complications and cerebral edema in diabetic ketoacidosis (DKA), and rapidly lowering blood ketone levels when combined with insulin.[4][7][1][2][10]
- Other names
- PMZ 2123PMZ2123PMZ-2123
02
Targets
EDNRA (Endothelin receptor type A)
Beyond the preview
Go deeper on PMZ-2123.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PMZ-2123.